Showing results (1-10 of 559) with videos related to
Sort By:
Pageof 56
Clinical Pharmacology and Therapeutics|March 5, 2010
Obesity, inflammation, and cardiovascular riskP Mathieu, I Lemieux, J-P DesprésInternational Journal of Obesity (2005)|March 30, 2006
Contribution of CB1 blockade to the management of high-risk abdominal obesityJ-P Després, I Lemieux, N AlmérasDiabetes & Metabolism|September 28, 1999
The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspectsB Lamarche, I Lemieux, J P DesprésAnnales D'Endocrinologie|January 10, 2001
[Risk factors associated with obesity: a metabolic perspective]J P Després, A Pascot, I LemieuxJournal of Internal Medicine|May 25, 2002
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trialJ-P Després, I Lemieux, H Salomon, et al.Atherosclerosis|February 13, 2001
HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular studyJ P Després, I Lemieux, G R Dagenais, et al.Diabetes & Metabolism|July 14, 2001
[Fat distribution and metabolism]J P Després, I Lemieux, A Tchernof, et al.Metabolism: Clinical and Experimental|October 27, 1999
Visceral adipose tissue and low-density lipoprotein particle size in middle-aged versus young menI Lemieux, A Pascot, A Tchernof, et al.European Journal of Clinical Investigation|January 22, 2003
Is the gender difference in LDL size explained by the metabolic complications of visceral obesity?I Lemieux, A Pascot, B Lamarche, et al.International Journal of Obesity (2005)|January 17, 2007
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese menM Côté, I Matias, I Lemieux, et al.Pageof 56